[HTML][HTML] Brain-gut axis in the pathogenesis of Helicobacter pylori infection

J Budzyński, M Kłopocka - World Journal of Gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
Helicobacter pylori (H. pylori) infection is the main pathogenic factor for upper digestive tract
organic diseases. In addition to direct cytotoxic and proinflammatory effects, H. pylori …

Contrast-enhanced ultrasound for detection of Crohn's disease activity: systematic review and meta-analysis

Z Serafin, M Białecki, A Białecka… - Journal of Crohn's …, 2016 - academic.oup.com
Abstract Background and Aims: Reports on imaging of active Crohn's disease (aCD) using
contrast-enhanced ultrasound (CEUS) are encouraging. However, the statistical power of …

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised …

S Vermeire, S Schreiber, R Petryka, T Kuehbacher… - The Lancet, 2017 - thelancet.com
Summary Background Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered,
Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and …

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

S Vermeire, WJ Sandborn, S Danese, X Hébuterne… - The Lancet, 2017 - thelancet.com
Background PF-00547659 is a fully human monoclonal antibody that binds to human
mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to selectively reduce lymphocyte …

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study

WJ Sandborn, SD Lee, D Tarabar, E Louis, M Klopocka… - Gut, 2018 - gut.bmj.com
Objective This phase II, randomised, double-blind, placebo-controlled clinical trial was
designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal …

Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence

J Budzyński, M Koziński, M Kłopocka… - Clinical Research in …, 2014 - Springer
Abstract Although Helicobacter pylori (Hp) primarily colonizes gastric mucosa, it can
occasionally inhabit in atherosclerotic plaques. Both forms of Hp infection may be involved …

Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study

S Danese, M Klopocka, EJ Scherl, J Romatowski… - Clinical …, 2021 - Elsevier
Background & Aims An immune component of inflammatory bowel disease is up-regulated
tumor necrosis factor-like ligand 1A (TL1A). Anti-TL1A antibodies such as PF-06480605, a …

Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab [SHP647] for the treatment of ulcerative colitis: the open-label study …

W Reinisch, WJ Sandborn, S Danese… - Journal of Crohn's …, 2021 - academic.oup.com
Abstract Background and Aims Ontamalimab, a fully-human monoclonal antibody targeting
MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in …

Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in …

M Łodyga, P Eder, M Gawron-Kiszka… - Gastroenterology …, 2021 - termedia.pl
This paper is an update of the diagnostic and therapeutic recommendations of the National
Consultant for Gastroenterology and the Polish Society of Gastroenterology from 2012. It …

[HTML][HTML] Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population

J Ostrowski, A Paziewska, I Lazowska… - Scientific reports, 2016 - nature.com
Most inflammatory bowel diseases (IBDs) are classic complex disorders represented by
common alleles. Here we aimed to define the genetic architecture of pediatric and adult …